| New Century Pharmaceuticals, Inc. is a biopharmaceutical company with an Oncology and Anti-infective focus which uses leading expertise in albumin structure and chemistry to improve drug safety and efficacy. NCP is currently advancing a number of important oncology product candidates through preclinical studies and commercializing through out-licensing and partnerships. |
- New Investment Opportunity: New Century Pharmaceuticals announces its pending August 2008 stock offering to fund the Company's first Phase I clinical trial. Read More >>
- June 2008, New Century Pharmaceuticals, Inc., one of the Hudson Alpha Associate Companies, establishes initial office presence at the Hudson Alpha Institutes new state-of-the-art facilities. Read More >>
- Bob Crutchfield, CEO of Third Trimester and former VP of US Oncology, is engaged by the Company as a senior advisor in support of business operations and development. Read More >>
- May 23, 2008 NCP successfully retires bridge financing through sale of its royalty interest in modular antibody platform licensed to f-star, an Austrian based biopharmaceutical company. Read More >>
|
